Details for Patent: 8,039,494

Which drugs does patent 8,039,494 protect, and when does it expire?

Patent 8,039,494 protects JUBLIA and is included in one NDA.

Summary for Patent: 8,039,494

Title:	Compositions and methods for treating diseases of the nail
Abstract:	Methods and compositions for treating disorders of the nail and nail bed. Such compositions contain a vehicle in which all components of the composition are dissolved, suspended, dispersed, or emulsified, a non-volatile solvent, a wetting agent, and a pharmaceutically active ingredient that is soluble in the non-volatile solvent and/or a mixture of the vehicle and the non-volatile solvent, which composition has a surface tension of 40 dynes/cm or less and has continuing spreadability, and which composition is effective in treating a disorder of the nail or nail bed.
Inventor(s):	Gareth Winckle, Gregory T. Fieldson
Assignee:	Bausch Health Ireland Ltd
Application Number:	US12/803,848
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,039,494
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;

US Patent 8,039,494: Scope, Claims, Expiration, and Efinaconazole Patent Landscape

US Patent 8,039,494 protects a low-surface-tension, non-film-forming topical nail treatment containing a triazole antifungal. Its commercially important embodiment is an efinaconazole formulation using ethanol, diisopropyl adipate, C12-15 alkyl lactate, and cyclomethicone. The patent is directed primarily to formulation performance and use in nail disorders, rather than to efinaconazole as a chemical entity.

The patent issued October 18, 2011, from an application claiming priority to September 2, 2008. Public patent records identify September 2, 2029, as the ordinary patent expiration date, subject to any applicable patent-term adjustment or extension reflected in official USPTO records.[1]

What does US Patent 8,039,494 protect?

The independent claim covers a method of treating a nail or nail-bed disorder by applying a defined topical composition to the nail surface. The composition must satisfy several limitations simultaneously:

Claim limitation	Required characteristic
Therapeutic use	Treatment of a nail or nail-bed disorder
Active ingredient	A triazole antifungal API
Vehicle	Volatile or rapidly nail-penetrating vehicle
Wetting agent	Present in the composition
Surface tension	40 dynes/cm or less
Film behavior	Does not form a solid film on the nail
Optional component	Non-volatile solvent dissolved, suspended, dispersed, or emulsified in the vehicle
Treatment result	Applied in an amount and for a time sufficient to ameliorate signs and symptoms

The claim is a method-of-treatment claim. It does not broadly claim every efinaconazole composition, every triazole antifungal, or every nail antifungal product. An accused product must be used in a manner that satisfies the method limitations, and the composition used in that treatment must meet the formulation limitations.

The claim uses “consisting essentially of.” That transitional phrase generally permits additional ingredients that do not materially affect the basic and novel characteristics of the claimed composition. Ingredients that materially change surface tension, evaporation, nail penetration, spreading, or film formation could create a claim-scope issue.

Which drug is covered by the patent?

Claim 7 identifies efinaconazole by its chemical structure:

(2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidine-1-yl)-1-(1H-1,2,4-triazole-1-yl)butane-2-ol.

Efinaconazole is the active ingredient in Jublia, a topical solution approved by the FDA for the treatment of onychomycosis of the toenails.[2] The chemical name in claim 9 contains an apparent typographical error involving the triazole notation, but claim 7 supplies the more precise structural definition.

Patent 8,039,494 therefore has high commercial relevance to Jublia even though its broadest independent claim is not limited to efinaconazole. A competing product using another triazole could fall within claim 1 if it satisfies the vehicle, wetting-agent, surface-tension, film-formation, and nail-treatment limitations.

How do the dependent claims narrow the patent scope?

The dependent claims progressively define the formulation and performance profile.

Claim	Added limitation	Commercial or technical significance
2	Vehicle and wetting agent are the same compound	Covers single-component vehicle/wetting systems
3	Wetting agent is a volatile silicone	Points toward cyclomethicone-type systems
4	Vehicle is an alcohol	Supports ethanol-based formulations
5	Non-polar, non-volatile solvent is present	Adds a persistent solvent phase
6	Non-volatile solvent is an ester within the specified carbon range	Defines a broad ester genus
7	Triazole is efinaconazole	Directly covers the Jublia API embodiment
8	Alcohol, ester solvent, and volatile silicone are all present	Core combination claim for the commercial formulation
9	Claim 8 composition contains efinaconazole	Commercially significant combination
10	Alcohol is ethanol	Narrows the vehicle to ethanol
11	Solvent includes diisopropyl adipate and C12-15 alkyl lactate	Closely tracks the Jublia formulation
12	Volatile silicone is cyclomethicone	Closely tracks the Jublia formulation
13	Disorder is onychomycosis	Aligns with the FDA-approved indication
14	No polymeric film-forming compound	Excludes lacquer-like formulations
15	Spread increases during the six minutes after application	Adds a dynamic spreading requirement
16	Spread exceeds 11.0 cm within 10 minutes after 100 microliters	Adds a quantitative spreading test
17	Surface tension is 35 dynes/cm or less	Tightens the surface-tension threshold
18	Surface tension is 30 dynes/cm or less	Further narrows the claim
19	Surface tension is 25 dynes/cm or less	Narrowest surface-tension limitation

Claim 8 is important because it defines the formulation architecture: an alcohol vehicle, a specified ester-based non-volatile solvent, and a volatile silicone wetting agent. Claims 9 through 12 then identify the efinaconazole, ethanol, diisopropyl adipate/C12-15 alkyl lactate, and cyclomethicone embodiment.

What formulation is most closely associated with US 8,039,494?

The formulation most closely aligned with claims 8 through 12 is:

Component	Claimed or associated role
Efinaconazole	Triazole antifungal API
Ethanol	Volatile alcohol vehicle
Diisopropyl adipate	Non-polar, non-volatile ester solvent
C12-15 alkyl lactate	Non-volatile ester solvent
Cyclomethicone	Volatile silicone wetting agent
Film former	Excluded by claim 14

This formulation differs technically from traditional nail lacquers. A nail lacquer commonly depends on a polymeric film that remains on the nail and acts as a drug reservoir. The claimed composition instead emphasizes rapid spreading, low surface tension, evaporation, and penetration without forming a solid film.

The absence of a polymeric film-forming compound is a meaningful design limitation. A formulation developer seeking to avoid the patent could evaluate a polymer-containing lacquer, but that approach may implicate other formulation patents, regulatory differences, slower application behavior, or separate freedom-to-operate concerns.

What are the key claim-construction issues?

Surface tension

Claim 1 requires surface tension of 40 dynes/cm or less. Claims 17 through 19 narrow the threshold to 35, 30, and 25 dynes/cm or less. Surface tension is a measurable physical property, but the result can depend on temperature, test method, instrument calibration, and sample handling.

For an infringement analysis, the testing protocol and measurement conditions would be material. A product measuring 39 dynes/cm under one protocol and above 40 dynes/cm under another could create a factual dispute.

“Does not form a solid film”

This limitation separates the claimed product from conventional film-forming nail lacquers. It requires analysis of the composition after application, including whether evaporation leaves a solid continuous film or only a residual deposit that does not meet the claim construction.

“Rapidly penetrates a nail”

The claim uses alternative vehicle characteristics: the vehicle may be volatile and/or rapidly penetrate the nail. A volatile vehicle can satisfy the first alternative without proving rapid nail penetration, although the full claim still requires the other limitations.

“Wetting agent”

A wetting agent generally reduces interfacial tension and improves spreading over the nail plate. Claim 3 identifies volatile silicone as one species. Claims 8 and 12 make the silicone component central to the narrower formulation.

“Consisting essentially of”

This limitation can permit excipients that do not materially alter the composition’s basic and novel characteristics. It may exclude an added ingredient that changes the composition from a rapidly spreading, non-film-forming solution into a conventional lacquer or materially changes its nail-penetration behavior.

When does US Patent 8,039,494 lose exclusivity?

Event	Date
Earliest claimed priority	September 2, 2008
US patent application filing	September 2, 2009, according to public patent-family records
Publication	March 4, 2010
Patent issuance	October 18, 2011
Ordinary 20-year expiration	September 2, 2029

The patent term is generally measured from the earliest effective US nonprovisional filing date, not simply from the issue date. Patent 8,039,494 therefore does not expire 20 years after issuance. Its commercial life is tied to the September 2009 filing date and the 2008 priority claim.[1]

Any patent-term adjustment would be added to the ordinary term. A patent-term extension under 35 U.S.C. § 156 is a separate issue and normally depends on regulatory review of the claimed product. The FDA approval of Jublia does not by itself establish that this patent received a patent-term extension.

What is the Orange Book status of US 8,039,494?

FDA Orange Book records identify US 8,039,494 in connection with Jublia, the efinaconazole topical solution approved under NDA 203567.[3] The listing gives the patent practical importance in an ANDA challenge because an applicant must address listed patents through a certification under the Hatch-Waxman framework.

The relevant certification possibilities are:

Certification	Effect
Paragraph I	No patent information is listed
Paragraph II	Patent has expired
Paragraph III	Applicant will wait until patent expiration
Paragraph IV	Patent is invalid, unenforceable, or will not be infringed
Section viii statement	Applicant omits a patented method of use where permitted

For a generic efinaconazole topical solution seeking the same onychomycosis indication, a Paragraph III certification could defer launch until patent expiration. A Paragraph IV certification could trigger patent litigation if the NDA holder sues within the statutory period.

An ANDA applicant could also evaluate a section viii strategy if the listed patent covers a method of use that the applicant seeks to omit. That strategy would be more difficult where the proposed label retains nail-disorder or onychomycosis language corresponding to the claimed method.

Which companies are associated with the patent and product?

Jublia was developed through the efinaconazole program associated with Kaken Pharmaceutical and Dow Pharmaceutical Sciences. Valeant Pharmaceuticals acquired Dow Pharmaceutical Sciences, and Valeant later became Bausch Health Companies.[4] Kaken has maintained a major role in efinaconazole development and commercialization outside the United States, while Bausch Health has marketed Jublia in the United States.

Entity	Role in the commercial and patent landscape
Kaken Pharmaceutical	Efinaconazole originator and international development partner
Dow Pharmaceutical Sciences	US dermatology development and commercialization platform associated with Jublia
Valeant Pharmaceuticals	Acquirer of Dow Pharmaceutical Sciences
Bausch Health Companies	Successor commercial organization for Jublia in the United States
FDA	NDA and Orange Book regulator
USPTO	Patent grant, term, and assignment authority

Assignment history and Orange Book ownership should be reviewed separately because the patent owner, exclusive licensee, NDA holder, and marketer may not be the same entity at every point in time.

How strong is the patent estate for efinaconazole?

Patent 8,039,494 is strongest against a product that reproduces the commercial formulation and treatment approach. The highest-risk profile would include:

1. Efinaconazole as the API.
2. Ethanol as the principal vehicle.
3. Diisopropyl adipate and C12-15 alkyl lactate.
4. Cyclomethicone.
5. Surface tension of 40 dynes/cm or less.
6. No solid polymeric film.
7. A label directing treatment of onychomycosis.

A product using efinaconazole but a materially different vehicle, wetting system, surface-tension profile, or film-forming technology may avoid some narrower claims. It would still require a claim-by-claim analysis of the independent claim and any related patents covering the efinaconazole molecule, formulation, manufacturing process, or dosage regimen.

The patent’s principal vulnerability is its fact-intensive physical-property limitations. Surface tension, spreading, penetration, and film formation can be tested. The same limitations also create design-around opportunities because a competitor can alter excipient selection or formulation behavior while retaining efinaconazole.

What generic entry risks exist?

Efinaconazole generic risk

Efinaconazole is a small molecule, so the relevant pathway is an ANDA or, in some circumstances, a 505(b)(2) application. Biosimilar analysis does not apply. A generic applicant would need to address pharmaceutical equivalence, topical product performance, labeling, and listed patents.

Paragraph IV litigation risk

A Paragraph IV filing could challenge the validity, enforceability, or infringement of US 8,039,494. Likely dispute points would include:

• Whether the proposed formulation has surface tension of 40 dynes/cm or less.
• Whether the vehicle is volatile or rapidly penetrates the nail.
• Whether the composition forms a solid film.
• Whether the accused wetting agent satisfies the claim.
• Whether the proposed use is treatment of a claimed nail disorder.
• Whether additional excipients materially alter the claimed composition under “consisting essentially of.”

A generic applicant could also seek a non-infringing formulation that does not meet the quantitative surface-tension or spreading limitations.

Generic launch scenarios

Scenario	Commercial result
Paragraph III certification	Launch delayed until patent expiry, absent earlier settlement or invalidation
Paragraph IV with no timely suit	Potential launch after statutory notice period and regulatory approval
Paragraph IV litigation with preliminary injunction	Launch may be delayed during litigation
Successful invalidity or non-infringement outcome	Earlier market entry possible
Settlement with licensed entry date	Entry governed by agreement terms
Non-infringing formulation	Entry depends on FDA approval and remaining patent barriers

What litigation and settlement issues affect the patent?

A complete litigation assessment must distinguish cases involving:

• US 8,039,494 itself.
• Other Jublia patents.
• Efinaconazole compound patents.
• Formulation or manufacturing patents.
• ANDA applicants.
• Patent ownership or licensing disputes.

The existence of an Orange Book listing does not establish that a Paragraph IV challenge has been filed. Public FDA and court records should be matched by patent number, NDA number, defendant, and filing date. A settlement agreement may provide an authorized-generic license, a delayed-entry date, or restrictions on the formulation and indication.

No biosimilar litigation is relevant because Jublia contains the small-molecule API efinaconazole rather than a biologic.

How does US 8,039,494 compare with other protection types?

Protection type	What it protects	Relevance to Jublia
Compound patent	Efinaconazole molecule or stereochemical form	Broad API protection
Formulation patent	Vehicle, solvents, wetting agent, surface tension, film behavior	Core subject of US 8,039,494
Method-of-use patent	Treatment of onychomycosis or another nail disorder	Controls labeled-use exposure
Manufacturing patent	Synthesis, purification, or formulation process	Can delay or complicate supply
Regulatory exclusivity	FDA approval rights	Operates independently from patent term
Trademark rights	Jublia brand	Commercial, not molecule or formulation exclusivity

US 8,039,494 is a formulation and method patent. It does not replace the need to review the full efinaconazole patent family or the complete Orange Book record.

Key Takeaways

• US 8,039,494 covers topical treatment of nail disorders with a low-surface-tension, non-film-forming triazole formulation.
• Claim 7 specifically identifies efinaconazole.
• Claims 8 through 12 closely track the Jublia formulation: ethanol, ester solvents, and cyclomethicone.
• Claim 13 expressly covers treatment of onychomycosis.
• Claims 15 and 16 add spreading-performance limitations that may be important in infringement testing.
• The ordinary expiration date is September 2, 2029, based on public patent-family records.
• The patent is relevant to ANDA Paragraph III and Paragraph IV strategies.
• Efinaconazole is a small molecule, so biosimilar litigation is not applicable.
• Formulation redesign may provide a potential design-around route, but other efinaconazole patents and Orange Book listings must also be assessed.
• The highest infringement risk involves a generic product that substantially reproduces the Jublia formulation and label.

FAQs About US Patent 8,039,494

Does US 8,039,494 claim efinaconazole itself?

No. It claims methods using a defined topical composition. Efinaconazole is expressly recited in dependent claim 7 and related dependent claims, but the patent is not a basic chemical compound patent.

Is US 8,039,494 a composition patent or a method patent?

It is principally a method-of-treatment patent. The claims define the composition used in the treatment, but infringement requires the claimed therapeutic method and formulation limitations.

Does a nail lacquer automatically infringe US 8,039,494?

No. The patent requires that the composition not form a solid film. A conventional polymeric nail lacquer may fall outside claims containing that limitation, although other patents may apply.

Can a generic use efinaconazole with a different solvent system?

Potentially. A different solvent system could avoid narrower claims, particularly claims 8 through 12. The independent claim would still require analysis of surface tension, vehicle behavior, wetting, film formation, and the proposed use.

What is the most commercially important claim?

Claims 9 through 12 are the most commercially specific because they combine efinaconazole with ethanol, diisopropyl adipate, C12-15 alkyl lactate, and cyclomethicone. Claim 1 remains important because it covers a broader class of triazole-based nail-treatment formulations.

References

1. United States Patent and Trademark Office. (2011). U.S. Patent No. 8,039,494, Topical compositions for treating nail disorders. https://patents.google.com/patent/US8039494B2/en
2. U.S. Food and Drug Administration. (2014). Jublia (efinaconazole) topical solution, 10%: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203567s000lbl.pdf
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
4. Bausch Health Companies Inc. (n.d.). Company history and product information. https://www.bauschhealth.com/

Drugs Protected by US Patent 8,039,494

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bausch	JUBLIA	efinaconazole	SOLUTION;TOPICAL	203567-001	Jun 6, 2014	AB	RX	Yes	Yes						ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS